JP2023527575A5 - - Google Patents

Info

Publication number
JP2023527575A5
JP2023527575A5 JP2022574098A JP2022574098A JP2023527575A5 JP 2023527575 A5 JP2023527575 A5 JP 2023527575A5 JP 2022574098 A JP2022574098 A JP 2022574098A JP 2022574098 A JP2022574098 A JP 2022574098A JP 2023527575 A5 JP2023527575 A5 JP 2023527575A5
Authority
JP
Japan
Prior art keywords
dimethyltryptamine
solid formulation
formulation according
pharmaceutically acceptable
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022574098A
Other languages
English (en)
Japanese (ja)
Other versions
JP7579888B2 (ja
JP2023527575A (ja
Filing date
Publication date
Priority claimed from US16/890,664 external-priority patent/US11771681B2/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from GBGB2018950.2A external-priority patent/GB202018950D0/en
Priority claimed from US17/108,679 external-priority patent/US20220168274A1/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Priority claimed from PCT/EP2021/060750 external-priority patent/WO2021116503A2/en
Application filed filed Critical
Publication of JP2023527575A publication Critical patent/JP2023527575A/ja
Publication of JP2023527575A5 publication Critical patent/JP2023527575A5/ja
Application granted granted Critical
Publication of JP7579888B2 publication Critical patent/JP7579888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022574098A 2020-06-02 2021-05-13 治療用固形製剤 Active JP7579888B2 (ja)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
GB2008303.6 2020-06-02
US16/890,664 US11771681B2 (en) 2019-06-03 2020-06-02 Therapeutic compounds
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
EPPCT/EP2020/065244 2020-06-02
US16/890,664 2020-06-02
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,679 US20220168274A1 (en) 2020-12-01 2020-12-01 Parenteral Formulation
US17/108,938 2020-12-01
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation
GB2018950.2 2020-12-01
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
US17/108,679 2020-12-01
GB2018955.1 2020-12-01
US17/208,583 2021-03-22
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
GB2103981.3 2021-03-22
PCT/EP2021/060750 WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds
EPPCT/EP2021/060750 2021-04-23
PCT/EP2021/062794 WO2021244831A1 (en) 2020-06-02 2021-05-13 Therapeutic solid dosage forms

Publications (3)

Publication Number Publication Date
JP2023527575A JP2023527575A (ja) 2023-06-29
JP2023527575A5 true JP2023527575A5 (cg-RX-API-DMAC7.html) 2024-04-16
JP7579888B2 JP7579888B2 (ja) 2024-11-08

Family

ID=76329655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574098A Active JP7579888B2 (ja) 2020-06-02 2021-05-13 治療用固形製剤

Country Status (8)

Country Link
EP (3) EP3902541B1 (cg-RX-API-DMAC7.html)
JP (1) JP7579888B2 (cg-RX-API-DMAC7.html)
CN (1) CN115996713A (cg-RX-API-DMAC7.html)
AU (1) AU2021284861B2 (cg-RX-API-DMAC7.html)
CA (1) CA3118556A1 (cg-RX-API-DMAC7.html)
GB (1) GB2595776B (cg-RX-API-DMAC7.html)
IL (1) IL298542B2 (cg-RX-API-DMAC7.html)
WO (2) WO2021116503A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20220797T1 (hr) 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
WO2022026223A1 (en) * 2020-07-29 2022-02-03 Gregory Ellis Delivery system for ayahuasca-like substances
JP2023539113A (ja) 2020-08-18 2023-09-13 サイビン アイアールエル リミテッド フェネチルアミン誘導体、組成物およびその使用方法
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4255421A1 (en) 2020-12-01 2023-10-11 Small Pharma Ltd Inhalable formulations
EP4031529B1 (en) * 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
WO2022120181A1 (en) 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4433049A1 (en) 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
CA3238440A1 (en) * 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
MX2024008691A (es) * 2022-01-14 2024-07-19 Cybin Irl Ltd Composiciones y metodos de triptamina.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
AU2023242469A1 (en) * 2022-03-31 2024-09-05 Cybin Irl Limited Combination of nitrous oxide and 5-ht2a receptor agonists
EP4522167A1 (en) 2022-05-10 2025-03-19 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20220797T1 (hr) * 2019-11-07 2022-10-14 Small Pharma Ltd Spojevi

Similar Documents

Publication Publication Date Title
JP2022535093A5 (cg-RX-API-DMAC7.html)
TWI765451B (zh) 作為erk抑制劑的螺環類化合物及其應用
IL298542B1 (en) Therapeutic solid dosage forms comprising deuterated n,n-dimethyltryptamine compounds and salts thereof
JP2023531311A5 (cg-RX-API-DMAC7.html)
EP1027363B1 (en) Adenosine a1-receptor agonists
ES2660831T3 (es) Derivados de imidazol condensados útiles como inhibidores de IDO
JP2004514663A5 (cg-RX-API-DMAC7.html)
JP2008526999A5 (cg-RX-API-DMAC7.html)
RU2012101947A (ru) Способы лечения и профилактики усталости
JP2020075939A5 (cg-RX-API-DMAC7.html)
JP6087367B2 (ja) 三環式化合物、それらを含む組成物およびそれらの使用
JP2012530779A5 (cg-RX-API-DMAC7.html)
JP2020063305A (ja) 持続時間が超短期、短期、または中期の非対称性逆転可能神経筋遮断物質
JP2007507494A5 (cg-RX-API-DMAC7.html)
JP2005527628A5 (cg-RX-API-DMAC7.html)
RU2008100019A (ru) Способ лечения чрезмерной дневной сонливости (варианты)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2024520654A5 (cg-RX-API-DMAC7.html)
JP2021504326A5 (cg-RX-API-DMAC7.html)
JP2024509981A5 (cg-RX-API-DMAC7.html)
JP2019529460A5 (cg-RX-API-DMAC7.html)
JP2011525185A5 (cg-RX-API-DMAC7.html)
JP2023542945A5 (cg-RX-API-DMAC7.html)
JP2022510587A5 (cg-RX-API-DMAC7.html)
JP2005532397A5 (cg-RX-API-DMAC7.html)